/stocks — the workspaceLOADING
All BLTE SEC filings, by type → · Earnings date & implied move · Search inside filings
BELITE BIO, INC (BLTE) is a pharmaceutical preparations company. 8 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind BLTE’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from BLTE’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as BLTE tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: .
A plain-English read on BLTE plus an auto-SWOT — built from BLTE's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate BLTE using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has BLTE been issuing shares? Offering history →
Projected from BLTE's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentBLTE files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
None of the 5 estimators could run on BLTE's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for BLTE. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for BLTE, so sector medians could not fill the gaps.
Every refusal recorded for BLTE → · How often we decline, and why →
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Volume against its own history: 76% of its last 252 sessions were lighter than the last one. Volume detail
No lawmaker has disclosed a trade in BLTE under the STOCK Act.
No tracked institution reported a position in BLTE in the latest 13F round.
Head office: San Diego, Canada · the company’s charter and its head office are in different countries.
Source: the cover page of BELITE BIO, INC’s 20-F filed 2026-03-31, on EDGAR. Filings checked 2026-11-02. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 10 sales in the last ~6 months, 8 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 2 were filed without it.
| Scholl Hendrik PeterChief Medical Officer | SELLplan | $83K | view → |
| Lin Yu-HsinChief Executive Officer | SELLplan | $19.1M | view → |
| Chuang Hao-YuanChief Financial Officer | SELLplan | $12.8M | view → |
| Chuang Hao-YuanChief Financial Officer | SELLplan | $66K | view → |
| Lin Yu-HsinChief Executive Officer | SELLplan | $66K | view → |
| Scholl Hendrik PeterChief Medical Officer | SELL | $1.5M | view → |
| Scholl Hendrik PeterChief Medical Officer | SELL | $1.4M | view → |
| MATA NATHAN L.Chief Scientific Officer | SELLplan | $102K | view → |
2 of the 2 checks that ran found nothing new for BLTE. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.